- Home
- CHSCN vs MRUS Comparison
CHSCN vs MRUS Comparison
Compare CHSCN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CHSCN
- MRUS
- Stock Information
- Founded
- CHSCN N/A
- MRUS 2003
- Country
- CHSCN United States
- MRUS Netherlands
- Employees
- CHSCN N/A
- MRUS 260
- Industry
- CHSCN Farming/Seeds/Milling
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- CHSCN Industrials
- MRUS Health Care
- Exchange
- CHSCN Nasdaq
- MRUS Nasdaq
- Market Cap
- CHSCN N/A
- MRUS 2.7B
- IPO Year
- CHSCN N/A
- MRUS 2016
- Fundamental
- Price
- CHSCN $25.15
- MRUS $39.60
- Analyst Decision
- CHSCN
- MRUS Strong Buy
- Analyst Count
- CHSCN 0
- MRUS 13
- Target Price
- CHSCN N/A
- MRUS $86.85
- AVG Volume (30 Days)
- CHSCN N/A
- MRUS 650.7K
- Earning Date
- CHSCN N/A
- MRUS 05-07-2025
- Dividend Yield
- CHSCN N/A
- MRUS N/A
- EPS Growth
- CHSCN N/A
- MRUS N/A
- EPS
- CHSCN N/A
- MRUS N/A
- Revenue
- CHSCN N/A
- MRUS $36,133,000.00
- Revenue This Year
- CHSCN N/A
- MRUS $37.72
- Revenue Next Year
- CHSCN N/A
- MRUS $48.47
- P/E Ratio
- CHSCN N/A
- MRUS N/A
- Revenue Growth
- CHSCN N/A
- MRUS N/A
- 52 Week Low
- CHSCN N/A
- MRUS $37.77
- 52 Week High
- CHSCN N/A
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- CHSCN 34.15
- MRUS 32.49
- Support Level
- CHSCN $24.97
- MRUS $39.00
- Resistance Level
- CHSCN $25.22
- MRUS $45.44
- Average True Range (ATR)
- CHSCN 0.14
- MRUS 2.44
- MACD
- CHSCN -0.03
- MRUS -0.93
- Stochastic Oscillator
- CHSCN 9.72
- MRUS 5.51
About CHSCN CHS Inc Preferred Class B Series 2 Reset Rate
CHS Inc is an integrated agricultural enterprise, that provides grain, food, and energy resources to businesses and consumers. Its Energy segment produces and provides wholesale distribution of petroleum products and transportation of those products. Its Ag segment, which is the key revenue driver, purchases and processes or resells grains and oilseeds; serves as a wholesaler and retailer of crop inputs; produces and markets ethanol. Its Nitrogen Production segment consists of equity method investment in CF Nitrogen, which entitles the purchase of up to a specified quantity of granular urea and UAN annually from CF Nitrogen. Geographically, the company derives maximum revenue from North America and the rest from South America, Asia Pacific, Europe, Middle East, and Africa (EMEA).
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.